Johnny C. Hong

Johnny C. Hong

Auto-generated profile, based on publicly available information

Johnny C. Hong

Department of Surgery, Division of Transplant Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Transplantation Proceedings
Verified
Journal Article
Closed access
FDFrancisco A. Durazo
Francisco A. Durazo
ANAllyssa A. Nicholas
Allyssa A. Nicholas
JMJennifer J. Mahaffey
Jennifer J. Mahaffey
SSShannon Sova
Shannon Sova
JEJohn J. Evans
John J. Evans
JHJohnny C. Hong
Johnny C. Hong

10 April 2023 in Liver Transplantation
Verified
Journal Article
Closed access
BTBenjamin V. Tran
Benjamin V. Tran
DMDimitrios Moris
Dimitrios Moris
DMDaniela Markovic
Daniela Markovic
HZHamed Zaribafzadeh
Hamed Zaribafzadeh
RHRicardo Henao
Ricardo Henao
VAVatche G. Agopian
Vatche G. Agopian
HCC recurrence following liver transplantation (LT) is highly morbid and occurs despite strict patient selection criteria. Individualized prediction of post-LT HCC recurrence risk remains an important need. Clinico-radiologic and pathologic data of 4981 patients with HCC undergoing LT from the US Multicenter HCC Transplant Consortium (UMHTC) were analyzed to develop a REcurrent Liver cAncer Prediction ScorE (RELAPSE). Multivariable Fine and Gray competing risk analysis and machine learning algorithms (Random Survival Forest and Classification and Regression Tree models) identified variables to model HCC recurrence. RELAPSE was externally validated in 1160 HCC LT recipients from the European Hepatocellular Cancer Liver Transplant study group. Of 4981 UMHTC patients with HCC undergoing LT, 71.9% were within Milan criteria, 16.1% were initially beyond Milan criteria with 9.4% downstaged before LT, and 12.0% had incidental HCC on explant pathology. Overall and recurrence-free survival at 1, 3, and 5 years was 89.7%, 78.6%, and 69.8% and 86.8%, 74.9%, and 66.7%, respectively, with a 5-year incidence of HCC recurrence of 12.5% (median 16 months) and non-HCC mortality of 20.8%. A multivariable model identified maximum alpha-fetoprotein (HR = 1.35 per-log SD, 95% CI,1.22–1.50, p < 0.001), neutrophil-lymphocyte ratio (HR = 1.16 per-log SD, 95% CI,1.04–1.28, p < 0.006), pathologic maximum tumor diameter (HR = 1.53 per-log SD, 95% CI, 1.35–1.73, p < 0.001), microvascular (HR = 2.37, 95%–CI, 1.87–2.99, p < 0.001) and macrovascular (HR = 3.38, 95% CI, 2.41–4.75, p < 0.001) invasion, and tumor differentiation (moderate HR = 1.75, 95% CI, 1.29–2.37, p < 0.001; poor HR = 2.62, 95% CI, 1.54–3.32, p < 0.001) as independent variables predicting post-LT HCC recurrence (C-statistic = 0.78). Machine learning algorithms incorporating additional covariates improved prediction of recurrence (Random Survival Forest C-statistic = 0.81). Despite significant differences in European Hepatocellular Cancer Liver Transplant recipient radiologic, treatment, and pathologic characteristics, external validation of RELAPSE demonstrated consistent 2- and 5-year recurrence risk discrimination (AUCs 0.77 and 0.75, respectively). We developed and externally validated a RELAPSE score that accurately discriminates post-LT HCC recurrence risk and may allow for individualized post-LT surveillance, immunosuppression modification, and selection of high-risk patients for adjuvant therapies.

1 January 2014 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
JHJohnny C. Hong
Johnny C. Hong
RVRobert Venick
Robert Venick
HYHasan Yersiz
Hasan Yersiz
PKPrawat Kositamongkol
Prawat Kositamongkol
FKFady M. Kaldas
Fady M. Kaldas
RBRonald W. Busuttil
Ronald W. Busuttil
Orthotopic liver transplantation (OLT) is a durable life-saving treatment for patients with irreversible liver disease. Donor availability is the principal factor limiting expansion of OLT. This is a particular problem in small children, with scarce availability of size-appropriate grafts. In the current era, the waiting list mortality rate for children younger than 6 years is 4 times higher than for children aged 11 to 17 years.1

1 October 2020 in International Journal of Surgery
Verified
Journal Article
Closed access
GSGonzalo Sapisochin
Gonzalo Sapisochin
TITommy Ivanics
Tommy Ivanics
VSVijay Subramanian
Vijay Subramanian
MDMajella Doyle
Majella Doyle
JHJulie K. Heimbach
Julie K. Heimbach
JHJohnny C. Hong
Johnny C. Hong
Cholangiocarcinoma (CCA) is a rare but devastating malignancy that presents late, and associated with a high mortality if untreated. CCA is locally aggressive and located in close proximity to vital structures i.e. the portal vein and hepatic artery. A complete extirpation of the tumor including microscopically detectable disease R0 resection offers the best possibility of long-term survival in patients with CCA. As such, the surgical approach to achieve a R0 resection is dictated by the location of the tumor and the presence of underlying liver disease. The present article focuses on the general principles of the multidisciplinary treatment of hilar and intrahepatic CCA.

1 June 2020 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
PDF file
JKJoohyun Kim
Joohyun Kim
MZMichael A. Zimmerman
Michael A. Zimmerman
JHJohnny C. Hong
Johnny C. Hong
Neuroendocrine tumors (NET) are rare neoplasms with generally indolent growth behavior. The liver is the most common site of NET metastasis. The NET metastatic spread to the liver are usually multiple tumors involving bilateral hemilivers. For patients with isolated NET metastasis to the liver, a complete extirpation (R0) resection of both the primary NET and liver metastasis provide the best chance of tumor recurrence-free patient survival. Orthotopic liver transplantation (OLT) presents a viable treatment option for patients with unresectable liver metastasis from NET. Post-OLT outcomes for the patients of NET with liver metastasis (5-year overall survival rate 47–71%) are comparable to those for other indications. However, the high rate of recurrence after OLT (31–57%) remains a clinical obstacle. As such, it is imperative to consider each patient individually and identify prognostic factors that would impact post-OLT outcomes. This article focuses on the role of OLT in the definitive treatment of metastatic liver NET, review patient selection criteria predictive of survival outcomes and post-OLT outcomes for patients.

1 October 2019 in Journal of Surgical Research
Verified
Journal Article
Closed access
MWMelissa Wong
Melissa Wong
JKJoohyun Kim
Joohyun Kim
BGBen George
Ben George
CECalvin Eriksen
Calvin Eriksen
TPTerra Pearson
Terra Pearson
JHJohnny C. Hong
Johnny C. Hong